India, April 8 -- Biotechnology company CytoDyn Inc. (CYDY.OB) announced Monday that it has enrolled and treated the first two COVID-19 patients with leronlimab under its Phase 2 randomized clinical trial, which is for patients with mild-to-moderate indications. The Company anticipates that enrollment of more patients will accelerate this week at multiple clinical sites.
The Phase 2 clinical trial is a randomized, double blind, placebo-controlled study to evaluate the efficacy and safety of leronlimab, and calls for 75 planned patients in up to 10 centers in the United States.
In addition, the company's investigational new drug leronlimab, which was granted emergency investigational new drug (EIND) status by the FDA, has now been administ...